Market Runner: Could Immune Design Corp Change Direction After Achieving Yearly Low?

Market Runner: Could Immune Design Corp Change Direction After Achieving Yearly Low?

The stock of Immune Design Corp (NASDAQ:IMDZ) hit a new 52-week low and has $4.36 target or 12.00% below today’s $4.95 share price. The 7 months bearish chart indicates high risk for the $121.28M company. The 1-year low was reported on Nov, 2 by Barchart.com. If the $4.36 price target is reached, the company will be worth $14.55M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 65,320 shares traded hands. Immune Design Corp (NASDAQ:IMDZ) has declined 59.62% since March 31, 2016 and is downtrending. It has underperformed by 62.14% the S&P500.

Analysts await Immune Design Corp (NASDAQ:IMDZ) to report earnings on November, 10. They expect $-0.68 earnings per share, down 83.78% or $0.31 from last year’s $-0.37 per share. After $-0.71 actual earnings per share reported by Immune Design Corp for the previous quarter, Wall Street now forecasts -4.23% EPS growth.

Immune Design Corp (NASDAQ:IMDZ) Ratings Coverage

Out of 2 analysts covering Immune Design (NASDAQ:IMDZ), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Immune Design has been the topic of 4 analyst reports since August 18, 2015 according to StockzIntelligence Inc. On Wednesday, August 10 the stock rating was maintained by Jefferies with “Buy”. The firm earned “Buy” rating on Wednesday, September 9 by Jefferies. The stock has “Outperform” rating given by Leerink Swann on Tuesday, August 18.

According to Zacks Investment Research, “Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on the development of immune-based therapies based on its DCVex (TM) and GLAAS (TM) discovery platforms for cancer and other chronic conditions. Its product candidates in Phase I clinical trials comprise LV305, CMB305, and G305 for the treatment of solid tumor types, such as breast cancer, melanoma, non-small cell lung cancer, ovarian cancer, or sarcoma; and G100 for the treatment of patients with merkel cell carcinoma. Immune Design Corp. is headquartered in Seattle, Washington.”

Insitutional Activity: The institutional sentiment increased to 1.25 in 2016 Q2. Its up 0.21, from 1.04 in 2016Q1. The ratio increased, as 8 funds sold all Immune Design Corp shares owned while 16 reduced positions. 8 funds bought stakes while 22 increased positions. They now own 9.57 million shares or 12.34% less from 10.92 million shares in 2016Q1.
The Switzerland-based Swiss Commercial Bank has invested 0% in Immune Design Corp (NASDAQ:IMDZ). Wells Fargo Mn owns 4,208 shares or 0% of their US portfolio. Tiaa Cref Inv Mgmt Limited Liability Com holds 0% or 43,523 shares in its portfolio. Manufacturers Life Insur The reported 803 shares or 0% of all its holdings. Nationwide Fund accumulated 0% or 10,378 shares. Bnp Paribas Arbitrage, a New York-based fund reported 436 shares. Morgan Stanley holds 4,828 shares or 0% of its portfolio. American Group holds 6,440 shares or 0% of its portfolio. The California-based Rs Management Ltd Liability Com has invested 0.1% in Immune Design Corp (NASDAQ:IMDZ). New York State Common Retirement Fund has invested 0% of its portfolio in Immune Design Corp (NASDAQ:IMDZ). Deutsche Financial Bank Ag last reported 32,864 shares in the company. Blackrock reported 60,355 shares or 0% of all its holdings. Moreover, Focused Wealth has 0.06% invested in Immune Design Corp (NASDAQ:IMDZ) for 15,868 shares. California State Teachers Retirement has 23,474 shares for 0% of their US portfolio. Blackrock Management Lc holds 0% of its portfolio in Immune Design Corp (NASDAQ:IMDZ) for 41,876 shares.

Insider Transactions: Since July 15, 2016, the stock had 4 insider purchases, and 0 sales for $10.26 million net activity. On Tuesday, September 20 Svennilson Peter bought $5.00M worth of the stock or 800,000 shares. COLUMN GROUP L P also bought $5.00 million worth of Immune Design Corp (NASDAQ:IMDZ) shares. Another trade for 40,000 shares valued at $250,000 was bought by COLEMAN LEWIS W. $10,255 worth of shares were bought by Brady Stephen R on Friday, July 15.

More important recent Immune Design Corp (NASDAQ:IMDZ) news were published by: Quotes.Wsj.com which released: “News Immune Design Corp.IMDZ” on July 23, 2014, also Globenewswire.com published article titled: “Immune Design Announces Advancement of First GLAASâ„¢-based Allergy Program …”, Globenewswire.com published: “Immune Design and Gritstone Oncology Announce Clinical Collaboration for …” on May 09, 2016. More interesting news about Immune Design Corp (NASDAQ:IMDZ) was released by: Globenewswire.com and their article: “Immune Design Announces Presentations at the 2016 American Society of Clinical …” with publication date: April 21, 2016.

IMDZ Company Profile

Immune Design Corp., incorporated on February 20, 2008, is a clinical-stage immunotherapy company. The Firm focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Firm is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo. The ZVex vector is a delivery system based on a hybrid, re-engineered virus designed to carry the genetic information of selected tumor antigen in whole or selected epitopes selectively to dendritic cells (DCs) in the skin. When injected into a cancer patient, a ZVex product candidate is designed to interact only with these DCs, delivering the tumor antigen in the form of ribonucleic acid (RNA).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment